Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01NIR
|
||||
| Former ID |
DIB007414
|
||||
| Drug Name |
Radotinib
|
||||
| Synonyms |
IY-5511; IY-GV50205; Anticancer, Il-yang
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Leukemia [ICD9: 208.9; ICD10:C90-C95] | Phase 3 | [1], [2] | ||
| Company |
Il-Yang Pharmaceutical Co
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C27H21F3N8O
|
||||
| InChI |
InChI=1S/C27H21F3N8O/c1-16-3-4-18(9-23(16)37-26-33-6-5-22(36-26)24-13-31-7-8-32-24)25(39)35-20-10-19(27(28,29)30)11-21(12-20)38-14-17(2)34-15-38/h3-15H,1-2H3,(H,35,39)(H,33,36,37)
|
||||
| InChIKey |
DUPWHXBITIZIKZ-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 926037-48-1
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Aurora protein kinase | Target Info | Modulator | ||
| KEGG Pathway | Oocyte meiosis | ||||
| Reactome | APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | ||||
| Separation of Sister Chromatids | |||||
| Resolution of Sister Chromatid Cohesion | |||||
| RHO GTPases Activate Formins | |||||
| WikiPathways | EGF/EGFR Signaling Pathway | ||||
| JAK/STAT | |||||
| Gastric Cancer Network 1 | |||||
| Integrated Breast Cancer Pathway | |||||
| APC/C-mediated degradation of cell cycle proteins | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01511289) Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7814). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.